Company profile
EDITAS MEDICINE, INC.
NASDAQ:EDITBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BRINRETIGENE VESGEDPARVOVEC | phase1_2 | — | 1 | unknown |
| RENIZGAMGLOGENE AUTOGEDTEMCEL | phase1_2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04853576 | phase1_2 | active_not_recruiting | 2021-05-04 | 2025-08-01 | Editas Medicine, Inc. | A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) |
| NCT05444894 | phase1_2 | active_not_recruiting | 2022-04-29 | 2025-09-01 | Editas Medicine, Inc. | EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) |
| NCT03872479 | phase1_2 | unknown | 2019-09-26 | 2025-05-23 | Editas Medicine, Inc. | Single Ascending Dose Study in Participants With LCA10 |
FDA applications (0)
No records yet.